All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Bookmark this article
The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Jonathan L. Kaufman, Emory University, Atlanta, US, answers the question: Is venetoclax, in combination with dexamethasone, efficacious for patients with t(11;14) relapsed/refractory multiple myeloma?
Jonathan Kaufman talks about the results of a study that examined the combination of venetoclax and dexamethasone in patients with t(11;14). He discusses the dosage regimen, safety, efficacy and overall response to the treatment.
Is venetoclax, in combination with dexamethasone, efficacious for patients with t(11;14) RRMM?
Does the VenDd +/- bortezomib combination represent a new treatment option for patients with RRMM?
Nizar Bahlis, University of Calgary, Calgary, CA, answers the question: Does the combination of venetoclax, daratumumab, dexamethasone, with or without...
ASH 2018 | Triplet combination of venetoclax, carfilzomib, and dexamethasone for relapsed/refractory multiple myeloma
A phase II study of venetoclax with carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma seems to be...
Subscribe to get the best content related to multiple myeloma delivered to your inbox